Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Mycenax Biotech Inc. (4726.TWO)
Zhubei, TW
Mycenax Biotech Inc. specializes in the research, development, and manufacturing of biopharmaceutical products, leveraging both mammalian and microbial cell culture systems. Its market reach extends across Taiwan, Europe, Asia, and the United States. The company cultivates a diverse portfolio of advanced biological therapeutics and components. This includes monoclonal antibodies, bi-specific antibodies, Fc-fusion proteins, recombinant proteins, peptides, non-toxic protein conjugates, antibody-cell conjugates, enzymes, antigen-binding fragments (Fab), and single-chain variable fragments (ScFv), in addition to plasmids and DNA vaccines. Beyond product innovation, Mycenax offers a comprehensive suite of process development solutions. These encompass the establishment of production cell lines, optimization of upstream and downstream processes, industrial scale-up, formulation science, and the creation of analytical methods. The firm also provides in-house analytical testing, Good Manufacturing Practice (GMP)-compliant manufacturing services for drug substances and finished products, and cell banking, all underpinned by its specialized manufacturing technologies. Established in 2001, Mycenax Biotech Inc. is headquartered in Zhubei, Taiwan.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -2.25% | +0.89% | -5.36% | -12.81% | -15.04% | -10.60% | -15.29% | -25.26% | -39.18% | -39.51% | +9.84% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+8.2% ★ Q1'26: +61.7% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+4.0% Q1'26: +9.7% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-41.1% Q1'26: +32.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%-54.6% Q1'26: -55.5% (vs Q1'25)
-
ROIC Biotechnology: -16.1%-16.5% Q1'26: -17.3% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.4% ★ Q1'26: +0.3% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-2.65× Q1'26: -2.45× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
149.00M
est.
|
149.00M
est.
|
207.13M
est.
|
348.24M
est.
|
390.84M
est: 350.00M (+11.7%)
|
665.34M
est: 661.00M (+0.7%)
|
774.27M
est: 740.00M (+4.6%)
|
732.28M
est: 622.00M (+17.7%)
|
652.62M
est: 844.00M (-22.7%)
|
683.92M
est: 830.00M (-17.6%)
|
740.24M
est: 740.00M (+0.0%)
|
1.02B
1.02B – 1.02B
+37.2% YoY
|
| EBITDA |
-16.86M
est.
|
-16.86M
est.
|
-23.44M
est.
|
-39.41M
est.
|
-122.74M
est: -39.61M (-209.9%)
|
176.90M
est: -74.80M (+336.5%)
|
82.83M
est: -83.74M (+198.9%)
|
-160.34M
est: -70.39M (-127.8%)
|
-339.48M
est: -95.51M (-255.4%)
|
-136.46M
est: -228.62M (+40.3%)
|
-403.84M
est: -203.83M (-98.1%)
|
-279.58M
-279.58M – -279.58M
-37.2% YoY
|
| EBIT |
-68.47M
est.
|
-68.47M
est.
|
-95.19M
est.
|
-160.04M
est.
|
-228.05M
est: -160.84M (-41.8%)
|
28.83M
est: -303.77M (+109.5%)
|
-84.99M
est: -340.07M (+75.0%)
|
-443.65M
est: -285.84M (-55.2%)
|
-654.26M
est: -387.86M (-68.7%)
|
-439.67M
est: -481.90M (+8.8%)
|
-403.84M
est: -429.64M (+6.0%)
|
-589.31M
-589.31M – -589.31M
-37.2% YoY
|
| Net Income |
-144.20M
est.
|
-144.20M
est.
|
-236.90M
est.
|
-80.34M
est.
|
-218.18M
est: -362.56M (+39.8%)
|
30.95M
est: 208.06M (-85.1%)
|
-89.86M
est: -61.80M (-45.4%)
|
-453.63M
est: -57.68M (-686.5%)
|
-682.85M
est: -372.86M (-83.1%)
|
-467.13M
est: -442.43M (-5.6%)
|
-448.63M
est: -465.17M (+3.6%)
|
-252.22M
-252.22M – -252.22M
+45.8% YoY
|
| SGA |
28.85M
est.
|
28.85M
est.
|
40.10M
est.
|
67.42M
est.
|
77.14M
est: 67.76M (+13.8%)
|
93.77M
est: 127.97M (-26.7%)
|
133.96M
est: 143.26M (-6.5%)
|
156.16M
est: 120.42M (+29.7%)
|
152.23M
est: 163.40M (-6.8%)
|
141.94M
est: 137.29M (+3.4%)
|
—
est: 122.41M (-100.0%)
|
167.89M
167.89M – 167.89M
+37.2% YoY
|
| EPS |
-0.70
est.
|
-0.70
est.
|
-1.15
est.
|
-0.39
est.
|
-1.74
est: -1.76 (+1.1%)
|
0.24
est: 1.01 (-76.2%)
|
-0.61
est: -0.30 (-103.3%)
|
-2.74
est: -0.28 (-878.6%)
|
-3.32
est: -1.81 (-83.4%)
|
-2.26
est: -2.14 (-5.6%)
|
-2.17
est: -2.25 (+3.6%)
|
-1.22
-1.22 – -1.22
+45.8% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-15 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-13 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-12 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-11 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-08 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-07 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-06 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-05 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-05-04 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-30 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Dimensional - Emerging Markets Core Equity 2 ETF DFEM | 0.00% | 11.3K | 0.39% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Pei-Jiun Chen | President Chief Executive Officer & Chairman | 7M | female |
| Chin-Hao Liang | Associate Vice President of Administration & Management Division | 3M | male |
| Wei-I Chou | Associate Vice President of Pharmaceutical Development Division | 3M | male |
| Liru Yeh | Assistant Vice President of Finance & Accounting Division | 3M | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 4726.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
